Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

US FDA Safety Labeling Change for mRNA COVID-19 Vaccines

14 Jul 2025

Abstract excerpt

This Viewpoint explores the US Food and Drug Administration’s institution of a class Safety Labeling Change for messenger RNA (mRNA) COVID-19 vaccines.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40658525
DOI: 10.1001/jama.2025.12675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

US FDA Safety Labeling Change for mRNA COVID-19 VaccinesPMID 40658525Read ↗

The dawn of mRNA vaccines: The COVID-19 caseSemantic proximity Read ↗

mRNA-based therapeutics: looking beyond COVID-19 vaccinesSemantic proximity Read ↗

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine LandscapeSemantic proximity Read ↗

mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!Semantic proximity Read ↗

Vaccines against COVID-19: Priority to mRNA-Based FormulationsSemantic proximity Read ↗

mRNA Vaccine Technology Beyond COVID-19Semantic proximity Read ↗

On the Shoulders of Giants — From Jenner’s Cowpox to mRNA Covid VaccinesSemantic proximity Read ↗

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccinesSemantic proximity Read ↗

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSemantic proximity Read ↗

Financing covid-19 mRNA vaccinesSemantic proximity Read ↗

The Importance of RNA-Based Vaccines in the Fight against COVID-19: An OverviewSemantic proximity Read ↗

mRNA: vaccine or gene therapy? The safety regulatory issuesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.